Document:

Exhibit
10.42

     

    November
9, 2009

    

    Mr. Jack
Spitz

    951
Longwood Club Place

    Longwood,
FL 32750

    

    Dear
Jack,

    

    On behalf
of NeoGenomics Laboratories (“NeoGenomics” or the “Company”), it is my pleasure
to extend this offer of employment for the Vice President of Laboratory
Operations position to you.  If the following terms are satisfactory,
please countersign this letter (the “Agreement”) and return a copy to me at your
earliest convenience.

    

    
      
        	
                Position:

              	 	
                Vice
      President (VP) of Laboratory Operations

              
	 
      	 	 
      
	
                Duties:

              	 	
                As
      VP of Lab Ops, you will report to the President of the Company or such
      other person as may be appointed by the President or CEO and you will be
      responsible for the laboratory’s technical, administrative and financial
      operations of the laboratory. This will include any/all lab sites the
      company has which currently include Ft. Myers, FL (corporate
      headquarters), Nashville, TN and Irvine, CA.  In addition you
      may be assigned other duties by the President or CEO, or by the Board’s
      designee in the absence of the President or CEO.

              
	 
      	 	 
      
	
                Start
      Date:

              	 	
                On
      or before December 7, 2009.

              
	 
      	 	 
      
	
                Base
    Salary:

              	 	
                $210,000/year,
      payable bi-weekly.  The parties agree that this salary is for a
      full-time position.  Increases in base salary may occur annually
      at the discretion of the President of the Company with the approval of the
      CEO and the Compensation Committee of the Board of
    Directors.

              
	 
      	 	 
      
	
                Relocation:

              	 	
                You
      will be eligible for relocation assistance should you agree to establish a
      residence in the greater Fort Myers area no later than December 1,
      2010.  Please refer to the terms in the attached Relocation
      Agreement.

              
	 
      	 	 
      
	
                Bonus:

              	 	
                Beginning
      with the fiscal year ending December 31, 2010, you will be eligible to
      receive an incentive bonus payment which will be targeted at 30% of your
      Base Salary based on 100% achievement of the goals set forth for you by
      the President or CEO of the Company and approved by the Board of Directors
      for such fiscal year.  Such goals will have overall company
      performance targets and individual performance
  targets.

              

      

    

    

    
      
        
          
            
              
                
                  
                    
                      	
                               

                              NeoGenomics Laboratories Florida

                            	 
      	 
      	
                               

                              NeoGenomics Laboratories California

                            
	
                              12701 Commonwealth Drive, Suite 5    •   Fort Myers, FL 33913

                            	 
      	 
      	
                              6 Morgan, Suite 150   •   Irvine, CA 92618

                            
	
                              Telephone: (866) 776-5907    •   Fax: (239) 768-0711

                            	 
      	 
      	
                              NeoGenomics Laboratories Tennessee

                            
	
                              www.neogenomics.org

                            	 
      	 
      	
                              618 Grassmere Park Drive Unit 20   •   Nashville, TN 37211

                            

                    

                  

                

              

            

          

        

      

    

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    

    
      
        
          	
                  Benefits:

                	 	
                  You
      will be entitled to participate in all medical and other benefits that the
      Company has established for its employees in accordance with the Company’s
      policy for such benefits at any given time.  Other benefits may
      include but not be limited to: short term and long term disability,
      dental, a 401K plan, a section 125 plan and an employee stock purchase
      plan.

                
	 
      	 	 
      
	
                  Paid
      Time Off:

                	 	
                  You
      will be eligible for 4 weeks of paid time off (PTO)/year (160 hours),
      which will accrue on a pro-rata basis beginning from your hire date and be
      may carried over from year to year.  It is company policy that
      when your accrued PTO balance reaches 160 hours, you will cease accruing
      PTO until your accrued PTO balance is 120 hours or less – at which point
      you will again accrue PTO until you reach 160 hours. You are eligible to
      use PTO after completing 3 months of employment. In addition to paid time
      off, there are also 6 paid national holidays and 1 “floater” day available
      to you.

                
	 
      	 	 
      
	
                  Stock
      Options:

                	 	
                  You
      will be granted stock options to purchase up to 150,000 shares of the
      common stock of the Company’s publicly-traded holding company,
      NeoGenomics, Inc., a Nevada corporation, at an exercise price equivalent
      to the closing price per share at which such stock was quoted on the
      NASDAQ Bulletin Board on the day prior to your Start Date. The grant of
      such options will be made pursuant to the Company’s stock option plan then
      in effect and will be evidenced by a separate Option Agreement, which the
      Company will execute with you within 60 days of receiving a copy of the
      Company’s Confidentiality, Non-Competition and Non-Solicitation Agreement
      which has been executed by you.  So long as you remained
      employed by the Company, such options will have a five-year term from the
      grant date and will vest according to the following
    schedule:

                
	 
      	 	 
      
	 
      	 	
                  Time-Based
      Vesting

                
	 
      	 	 
      
	 
      	 	
                  37,500    options
      will vest at the first year anniversary of your Start
  Date

                
	 
      	 	 
      
	 
      	 	
                  3,125      options
      will vest each month beginning on the 13th monthly anniversary of your
      Start Date and continuing on each monthly anniversary thereafter until the
      fourth anniversary of your Start Date

                
	 
      	 	 
      
	 
      	 	
                  If
      for any reason you resign prior to the time which is 12 months from your
      Start Date, you will forgo all such options. Furthermore, you understand
      that the Company’s stock option plan requires that any employee who leaves
      the employment of the Company will have no more than three (3) months from
      their termination date to exercise any vested options.

                
	 
      	 	 
      
	 
      	 	
                  The
      Company agrees that it will grant to you the maximum number of Incentive
      Stock Options (“ISO’s”) available under current IRS guidelines and that
      the remainder, if any, will be in the form of non-qualified stock
      options.

                

        

      

    

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    

    
      
        	
                Termination
Without
      Cause:

              	 	
                 

                If
      the Company terminates you without “Cause” for any reason during the Term
      or any extension thereof, then the Company agrees that as severance it
      will continue to pay you your Base Salary and maintain your employee
      benefits for a period that is equal to six (6) months of your employment
      by the Company, beginning on the date of your termination
      notice.

              
	 
      	 	 
      
	 
      	 	
                For
      the purposes of this letter agreement, the Company shall have “Cause” to
      terminate your employment hereunder upon:  (i) failure to
      materially perform

              
	 
      	 	
                and
      discharge your duties and responsibilities under this Agreement (other
      than any such failure resulting from incapacity due to illness) after
      receiving written notice and allowing you ten (10) business days to cure
      such failures, if so curable, provided, however, that after one such
      notice has been given to you, the Company is no longer required to provide
      time to cure subsequent failures under this provision, or (ii) any breach
      by you of the provisions of this Agreement; or (iii) misconduct which, in
      the opinion and sole discretion of the Company, is injurious to the
      Company; or (iv) any felony conviction involving the personal dishonesty
      or moral turpitude, or (v) engagement in illegal drug use or alcohol abuse
      which prevents you from performing your duties in any manner, or (vi) any
      material misappropriation, embezzlement or conversion of the Company’s or
      any of its subsidiary’s or affiliate’s property or business opportunities
      by you; or (vii) willful misconduct by you in respect of your duties or
      obligations under this Agreement and/or the Confidentiality,
      Non-Solicitation, and Non-competition Agreement.

              
	 
      	 	 
      
	 
      	 	
                You
      acknowledge and agree that any and all payments to which you are entitled
      under this Section are conditioned upon and subject to your execution of a
      general waiver and release, in such reasonable form as counsel for each of
      the Company and you shall agree upon, of all claims you have or may have
      against the Company.

              
	 
      	 	 
      
	
                Confidentiality,

                Non-Compete,
      &
Work +Products:

              	 	
                 

                 

                You
      agree that prior to your Start Date, you will execute the Company’s
      Confidentiality, Non-Competition and Non-Solicitation Agreement attached
      to this letter as Exhibit 1.  You understand that if you should
      fail to execute such Confidentiality, Non-Competition and Non-Solicitation
      Agreement in the agreed-upon form, it will be grounds for revoking this
      offer and not hiring you.  You understand and acknowledge that
      this Agreement shall be read in pari materia with
      the Confidentiality, Non-Competition and Non-Solicitation Agreement and is
      part of this Agreement.

              
	 
      	 	 
      
	
                Executive’s

                Representations:

              	 	
                 

                You
      understand and acknowledge that this position is an officer level position
      within NeoGenomics.  You represent and warrant, to the best of
      your knowledge, that nothing in your past legal and/or work experiences,
      which if became broadly known in the marketplace, would impair your
      ability to serve as an officer of a public company or materially damage
      your credibility with public shareholders.  You further
      represent and warrant, to the best of your knowledge, that, prior to
      accepting this offer of employment, you have disclosed all material
      information about your past legal and work experiences that would be
      required to be disclosed on a Directors’ and Officers’ questionnaire for
      the purpose of determining what disclosures, if any, will need to be made
      with the SEC.  Prior to the Company’s next public filing, you
      also agree to fill out a Director’s and Officer’s questionnaire in form
      and substance satisfactory to the Company’s counsel.   You
      further represent and warrant, to the best of your knowledge, that you are
      currently not obligated under any form of non-competition or
      non-solicitation agreement which would preclude you from serving in the
      position indicated above for NeoGenomics or soliciting business
      relationships for any laboratory services from any potential customers in
      the United States.

              

      

    

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    

    
      
        
          	
                  Miscellaneous:

                	 	(i)	
                  This
      Agreement supersedes all prior agreements and understandings between the
      parties and may not be modified or terminated orally.  No
      modification or attempted waiver will be valid unless in writing and
      signed by the party against whom the same is sought to be
      enforced.

                
	 
      	 	 	 
      
	 
      	 	(ii)	
                  The
      provisions of this Agreement are separate and severable, and if any of
      them is declared invalid and/or unenforceable by a court of competent
      jurisdiction or an arbitrator, the remaining provisions shall not be
      affected.

                
	 
      	 	 	 
      
	 
      	 	(iii)	
                  This
      Agreement is the joint product of the Company and you and each provision
      hereof has been subject to the mutual consultation, negotiation and
      agreement of the Company and you and shall not be construed for or against
      either party hereto.

                
	 
      	 	 	 
      
	 
      	 	(iv)	
                  This
      Agreement will be governed by, and construed in accordance with the
      provisions of the law of the State of Florida, without reference to
      provisions that refer a matter to the law of any other
      jurisdiction.  Each party hereto hereby irrevocably submits
      itself to the exclusive personal jurisdiction of the federal and state
      courts sitting in Florida; accordingly, any matters involving the Company
      and the Executive with respect to this Agreement may be adjudicated only
      in a federal or state court sitting in Lee County,
  Florida.

                
	 
      	 	 	 
      
	 
      	 	(v)	
                  This
      Agreement may be signed in counterparts, and by fax or by PDF, each of
      which shall be an original, with the same effect as if the signatures
      thereto and hereto were upon the same instrument

                
	 
      	 	 	 
      
	 
      	 	(vi)	
                  Within
      three days of your start date, you will need to provide documentation
      verifying your legal right to work in the United States.  Please
      understand that this offer of employment is contingent upon your ability
      to comply with the employment verification requirements under federal laws
      and that we cannot begin payroll until this requirement has been
      meet.

                
	 
      	 	 	 
      
	 
      	 	(vii)	
                  Employment
      with NeoGenomics is an “at-will” relationship and not guaranteed for any
      term.  You or the Company may terminate employment at anytime
      for any reason.

                

        

      

    

    

    (Signatures
Appear on the Next Page)

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    Jack, I
know that with your help we can build a world-class laboratory with a national
footprint and a team focused on the highest quality standards.  I am
looking forward to working with you as we drive NeoGenomics to new
heights.  Welcome aboard!

    

    Sincerely,

    

    Robert
Gasparini, M.S., CLSp (CG), CLDir

    President
and Chief Scientific Officer

    

    Agreed
and Accepted:

    

    
      
        
          
            	 
      	 
      	 
      
	
                    Jack
      Spitz

                  	 
      	
                    Date

                  

          

        

      

    

    
      
         

      

      
        5Exhibit
10.43

       

      THIRD AMENDMENT TO REVOLVING
CREDIT AND SECURITY AGREEMENT

       

      THIS
THIRD AMENDMENT TO REVOLVING CREDIT AND SECURITY AGREEMENT (this “Agreement”) is entered into on
this 26th day of
March 2010 (the “Effective
Date”), by and among NEOGENOMICS LABORATORIES,
INC., a Florida corporation formerly known as NeoGenomics, Inc. (“Borrower”), NEOGENOMICS, INC., a Nevada
corporation (“Guarantor”, together with
Borrower, each individually a “Credit Party” and
collectively, the “Credit
Parties”), and CAPITALSOURCE FINANCE LLC, a
Delaware limited liability company, as agent for the lender under the Credit
Agreement referred to below (“Agent”).

       

      RECITALS

       

      A.          Credit
Parties and CapitalSource Finance LLC (together with its successors and assigns,
“CSF”) have entered into
that certain Revolving Credit and Security Agreement, dated as of February 1,
2008 as amended by that certain First Amendment to Revolving Credit and Security
Agreement dated November 3, 2008 and that certain Second Amendment to Revolving
Credit and Security Agreement dated April 14, 2009 (as may be amended, restated,
supplemented, or otherwise modified from time to time, the “Credit
Agreement”).

       

      B.           Pursuant
to Section 15.2
of the Credit Agreement, CSF assigned the Revolving Facility to CapitalSource
Bank (“Lender”).

       

      C.           Pursuant
to Section
15.12 of the Credit Agreement, Lender has designated Agent as its agent
for taking certain actions under the Loan Agreement.

       

      D.          Credit
Parties have requested that Agent agree to make certain amendments to the Credit
Agreement.  Agent has agreed to this request on the conditions set
forth in this Agreement.

       

      E.           Pursuant
to the terms and conditions of this Agreement, Credit Parties and Agent have
agreed to amend certain provisions of the Credit Agreement.

       

      NOW,
THEREFORE, in consideration of the premises herein contained and other good and
valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties, intending to be legally bound, agree as
follows:

       

      AGREEMENT

       

      ARTICLE
I -
DEFINITIONS

       

      1.01  
    General
Terms.  Capitalized terms used in this Agreement are defined in
the Credit Agreement, as amended hereby, unless otherwise stated.

       

      
        
           

        

        
          
          

          
            

          

        

        
           

        

      

      ARTICLE
II– WAIVER AND
CONSENT

       

      2.01  
    Waiver.

       

      (a)           Events
of Default have occurred and are continuing under the Credit Agreement due to
the failure of Borrower to comply with the Fixed Charge Coverage Ratio covenant
set forth in Section 1 of Annex I to the Loan Agreement for the Test Periods
ending January 31, 2010 and February 28, 2010 (the “Specified Events of
Default”);

       

      (b)           Subject
to the conditions contained herein, Agent hereby waives the Specified Events of
Default.  Except as expressly set forth herein with respect to the
Specified Events of Default, this letter agreement shall not be deemed to be a
waiver of any Default or Events of Default.  The waiver set forth
herein shall not preclude the future exercise of any other right, power, or
privilege available to Agent or Lender whether under the Credit Agreement, the
Loan Documents or otherwise.

       

      ARTICLE
III-
AMENDMENTS

       

      3.01    
  Amendments
to Annex I of the Credit Agreement.  Effective as of the
Effective Date, Annex
I of the Credit Agreement is hereby amended by:

       

      (a)           deleting
the definition of Fixed Charge Coverage Ratio in Annex I in its
entirety and replacing it with the following:

       

      “Fixed Charge Coverage
Ratio” shall mean for Borrower collectively on a consolidated basis (a)
as of any date of determination occurring during the period from the Closing
Date through and including the Second Amendment Date the ratio of (i) Adjusted
EBITDA for the Test Period ended as of such date to (ii) Fixed charges for the
Test Period ended on such date; provided, that, solely for
purposes of calculating the Fixed Charge Coverage Ratio for the Test Periods
ending January 31, 2009 and February 28, 2009, the amount of Adjusted EBITDA for
such Test Periods shall be increased by an amount equal to the sum of (A)
$90,000 with respect to recruiting expenses, plus (B) $309,400
with respect to write-offs of bad debt, plus (C) $56,000 with
respect to bonus accrual, (b) as of any date of determination occurring during
the period after the Second Amendment Date to and including December 31, 2009
and for the Test Period ending March 31, 2010 the ratio of (i) the sum
of Adjusted EBITDA for the Test Period ended as of such date plus an amount equal
to the sum of unrestricted cash on hand, unrestricted Cash Equivalents and
unused Availability as of the last day of the Test Period ended as of such date,
to (ii) Fixed Charges for the Test Period ended as of such date; and (c) as of
any date of determination occurring after December 31, 2009, except for the Test
Period ending March 31, 2010 which shall be as specified above in (b), the ratio
of (i) Adjusted EBITDA for the Test Period ended as of such date to (ii)
Fixed Charges for the Test Period ended as of such date.

      
        
           

        

        
          2

          
            

          

        

        
           

        

      

      ARTICLE
IV- CONDITIONS PRECEDENT

       

      4.01   
   Conditions
to Effectiveness.  The effectiveness
of this Agreement against Lender is subject to the satisfaction of the following
conditions precedent in a manner satisfactory to Agent in its sole discretion,
unless specifically waived in writing by Agent:

       

      (a)           Agent
shall have received this Agreement duly executed by each party thereto;
and

       

      (b)           Agent
shall have received the Amendment Fee (as hereinafter defined).

       

      ARTICLE
V-
RATIFICATIONS, REPRESENTATIONS AND WARRANTIES

       

      5.01 
     Ratifications.  The terms and
provisions set forth in this Agreement shall modify and supersede all
inconsistent terms and provisions set forth in the Credit Agreement and the Loan
Documents, and, except as expressly modified and superseded by this Agreement,
the terms and provisions of the Credit Agreement and the Loan Documents are
ratified and confirmed and shall continue in full force and
effect.  The Credit Parties hereby ratify and confirm that the Liens
granted under the Credit Agreement secure all obligations and indebtedness now,
hereafter or from time to time made by, owing to or arising in favor of Lender
pursuant to the Loan Documents (as now, hereafter, or from time to time
amended).  Credit Parties and Agent agree that the Credit Agreement
and the Loan Documents, as amended hereby, shall continue to be legal, valid,
binding and enforceable in accordance with their respective terms.

       

      5.02    
  Representations
and Warranties.  The Credit
Parties hereby represent and warrant to Agent that:

       

      (a)           The
representations and warranties made by Borrower (other than those made as of a
specific date) contained in the Credit Agreement, as amended hereby, and each
Loan Document are true and correct in all material respects (except that, for
those representations and warranties already qualified by concepts of
materiality, those representations and warranties shall be true and correct in
all respects) on and as of the date hereof and as of the date of execution
hereof as though made on and as of each such date;

       

      (b)           No
Default or Event of Default under the Credit Agreement, as amended hereby, has
occurred and is continuing, except for the Specified Events of
Default;

       

      (c)           Other
than as contemplated hereby, Borrower has not amended its certificate of
incorporation or bylaws (or any other equivalent governing agreement or
document), as applicable, since the date of the Credit
Agreement.

      
        
           

        

        
          3

          
            

          

        

        
           

        

      

      ARTICLE
VI- AMENDMENT
FEE

       

      6.01    
  Amendment
Fee.  Borrower agrees to pay to Lender $25,000 as an amendment
fee (the “Amendment
Fee”), which fee shall be due and payable on the date
hereof.  Borrower hereby authorizes Agent to charge such fee as an
Advance on the date hereof and shall be fully earned by Lender when so charged
and which fee shall be credited toward the closing of a two year extension of
the Revolving Facility if such extension is approved by Lender in its sole
discretion.

       

      ARTICLE
VII-
MISCELLANEOUS PROVISIONS

       

      7.01 
     Survival
of Representations and Warranties.  All
representations and warranties made in the Credit Agreement, or any Loan
Document, including, without limitation, any document furnished in connection
with this Agreement, shall survive the execution and delivery of this Agreement
and the Loan Documents, and no investigation by Agent or Lender or any closing
shall affect the representations and warranties or the right of Agent or Lender
to rely upon them.

       

      7.02  
    Reference
to Credit Agreement.  Each of the
Credit Agreement and the Loan Documents, and any and all Loan Documents,
documents or instruments now or hereafter executed and delivered pursuant to the
terms hereof or pursuant to the terms of the Credit Agreement, as amended
hereby, are hereby amended so that any reference in the Credit Agreement and
such Loan Documents to the Credit Agreement shall mean a reference to the Credit
Agreement, as amended hereby.

       

      7.03  
    Expenses
of Agent or Lender.  As provided in
the Credit Agreement, the Credit Parties agree to pay on demand all costs and
expenses incurred by each of Agent and Lender in connection with the
preparation, negotiation, and execution of this Agreement and the Loan Documents
executed pursuant hereto and any and all amendments, modifications, and
supplements thereto, including, without limitation, the reasonable costs and
fees of Agent and Lender’s legal counsel, and all costs and expenses incurred by
Agent and Lender in connection with the enforcement or preservation of any
rights under the Credit Agreement, as amended hereby, or any Loan Documents,
including, without, limitation, the reasonable costs and fees of Agent and
Lender’s legal counsel.

       

      7.04  
    Severability.  Any provision of
this Agreement held by a court of competent jurisdiction to be invalid or
unenforceable shall not impair or invalidate the remainder of this Agreement and
the effect thereof shall be confined to the provision so held to be invalid or
unenforceable.

       

      7.05  
    Successors
and Assigns.  This Agreement is
binding upon and shall inure to the benefit of Agent, Lender and Credit Parties
and their respective successors and assigns, except that Credit Parties may not
assign or transfer any of their rights or obligations hereunder without the
prior written consent of Agent.

      
        
           

        

        
          4

          
            

          

        

        
           

        

      

      7.06   
   Counterparts.  This Agreement
may be executed in one or more counterparts, each of which when so executed
shall be deemed to be an original, but all of which when taken together shall
constitute one and the same instrument.  Any signature delivered by a
party by facsimile or other electronic transmission shall be deemed to be an
original signature hereto.

       

      7.07  
    Effect of
Waiver.  No consent or
waiver, express or implied, by Agent or Lender to or for any breach of or
deviation from any covenant or condition by Borrower shall be deemed a consent
to or waiver of any other breach of the same or any other covenant, condition or
duty.

       

      7.08  
    Headings.  The headings,
captions, and arrangements used in this Agreement are for convenience only and
shall not affect the interpretation of this Agreement.

       

      7.09      Applicable
Law.  THIS AGREEMENT
AND ALL LOAN DOCUMENTS EXECUTED PURSUANT HERETO SHALL BE DEEMED TO HAVE BEEN
MADE AND TO BE PERFORMABLE IN AND SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE CHOICE OR LAW SET FORTH IN THE CREDIT
AGREEMENT.

       

      7.10  
    Final
Agreement.  THE CREDIT
AGREEMENT AND THE LOAN DOCUMENTS, EACH AS AMENDED HEREBY, REPRESENT THE ENTIRE
EXPRESSION OF THE PARTIES WITH RESPECT TO THE SUBJECT MATTER HEREOF ON THE DATE
THIS AGREEMENT IS EXECUTED.  THE CREDIT AGREEMENT AND THE LOAN
DOCUMENTS, AS AMENDED HEREBY, MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR,
CONTEMPORANEOUS OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES.  THERE
ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES.  NO
MODIFICATION, RESCISSION, WAIVER, RELEASE OR AGREEMENT OF ANY PROVISION OF THIS
AGREEMENT SHALL BE MADE, EXCEPT BY A WRITTEN AGREEMENT SIGNED BY THE CREDIT
PARTIES AND AGENT.

       

      7.11 
     Release.  EACH CREDIT PARTY
HEREBY ACKNOWLEDGES THAT IT HAS NO DEFENSE, COUNTERCLAIM, OFFSET,
CROSS-COMPLAINT, CLAIM OR DEMAND OF ANY KIND OR NATURE WHATSOEVER THAT CAN BE
ASSERTED TO REDUCE OR ELIMINATE ALL OR ANY PART OF ITS LIABILITY TO REPAY THE
“OBLIGATIONS” OR TO SEEK AFFIRMATIVE RELIEF OR DAMAGES OF ANY KIND OR NATURE
FROM AGENT OR LENDER.  EACH CREDIT PARTY HEREBY VOLUNTARILY AND
KNOWINGLY RELEASES AND FOREVER DISCHARGES AGENT, LENDER, AND ANY OF ITS OR THEIR
RESPECTIVE PREDECESSORS, AGENTS, ATTORNEYS, EMPLOYEES, AFFILIATES, SUCCESSORS
AND ASSIGNS, FROM ALL POSSIBLE CLAIMS, DEMANDS, ACTIONS, CAUSES OF ACTION,
DAMAGES, COSTS, EXPENSES, AND LIABILITIES WHATSOEVER, KNOWN OR UNKNOWN,
ANTICIPATED OR UNANTICIPATED, SUSPECTED OR UNSUSPECTED, FIXED, CONTINGENT, OR
CONDITIONAL, AT LAW OR IN EQUITY, ORIGINATING IN WHOLE OR IN PART ON OR BEFORE
THE DATE THIS AGREEMENT IS EXECUTED, WHICH BORROWER MAY NOW OR HEREAFTER HAVE
AGAINST AGENT, LENDER, OR ANY OF ITS RESPECTIVE PREDECESSORS, ATTORNEYS, AGENTS,
EMPLOYEES, AFFILIATES, SUCCESSORS AND ASSIGNS, IF ANY, AND IRRESPECTIVE OF
WHETHER ANY SUCH CLAIMS ARISE OUT OF CONTRACT, TORT, VIOLATION OF LAW OR
REGULATIONS, OR OTHERWISE, AND ARISING FROM ANY “LOANS”, INCLUDING, WITHOUT
LIMITATION, ANY CONTRACTING FOR, CHARGING, TAKING, RESERVING, COLLECTING OR
RECEIVING INTEREST IN EXCESS OF THE HIGHEST LAWFUL RATE APPLICABLE, THE EXERCISE
OF ANY RIGHTS AND REMEDIES UNDER THE CREDIT AGREEMENT OR LOAN DOCUMENTS, AND
NEGOTIATION FOR AND EXECUTION OF THIS AGREEMENT.

       

      [REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]

      
        
           

        

        
          5

          
            

          

        

        
           

        

      

      IN
WITNESS WHEREOF, this Agreement has been executed and is effective as of the
date first written above.

       

      
        
          
            
              
                	 
      	
                        BORROWER:

                      
	 
      	 
      
	 
      	
                        NEOGENOMICS
      LABORATORIES, INC.,

                      
	 
      	
                        a
      Florida corporation

                      
	 
      	 
      
	 
      	
                        By:

                      	
                          

                      
	 
      	
                        Name:

                      	
                          

                      
	 
      	
                        Title:

                      	
                          

                      
	 
      	 
      	 
      
	 
      	
                        GUARANTOR:

                      
	 
      	 
      
	 
      	
                        NEOGENOMICS,
      INC., a Nevada corporation

                      
	 
      	 
      
	 
      	
                        By:

                      	
                          

                      
	 
      	
                        Name:

                      	
                          

                      
	 
      	
                        Title:

                      	
                          

                      
	 
      	 
      
	 
      	
                        CAPITALSOURCE
      FINANCE LLC, as Agent

                      
	 
      	 
      
	 
      	
                        By:

                      	
                          

                      
	 
      	
                        Name:

                      	
                          

                      
	 
      	
                        Title:

                      	
                          

                      

              

            

          

        

      

       

      
        
           

        

        
          6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}]]